Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. New England Journal Of Medicine 2015, 373: 1627-1639. PMID: 26412456, PMCID: PMC5705936, DOI: 10.1056/nejmoa1507643.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survival rateOverall survivalNivolumab groupDocetaxel groupLung cancerAdvanced nonsquamous non-small cell lung cancerNonsquamous non-small cell lung cancerSurvival rateNon-small cell lung cancerInternational phase 3 studyPD-1-mediated signalingPlatinum-based doublet chemotherapyTreatment-related adverse eventsEnd pointAdvanced nonsquamous NSCLCMedian overall survivalPrimary end pointPD-1 ligandsPhase 3 studyPlatinum-based chemotherapyCell lung cancerBody surface areaDoublet chemotherapyNonsquamous NSCLC